Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Wouter A P, Breeman"'
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 4, Iss 1, Pp 1-13 (2019)
Abstract Background Clinically applied radiopharmaceuticals have to meet quality release criteria like a high radiochemical yield and radiochemical purity. Many radiopharmaceuticals do not have marketing authorization and have no dedicated monograph
Externí odkaz:
https://doaj.org/article/141e9329f65147aa821d8049aea5c156
Autor:
Ho Sze Chan, Erik de Blois, Mark W. Konijnenberg, Alfred Morgenstern, Frank Bruchertseifer, Jeffrey P. Norenberg, Fred J. Verzijlbergen, Marion de Jong, Wouter A. P. Breeman
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 1, Iss 1, Pp 1-15 (2016)
Abstract Background 213Bismuth (213Bi, T1/2 = 45.6 min) is one of the most frequently used α-emitters in cancer research. High specific activity radioligands are required for peptide receptor radionuclide therapy. The use of generators containing le
Externí odkaz:
https://doaj.org/article/d7180907a14a49deaffb973b6e210c3c
Publikováno v:
Nuclear medicine and biology.
To purify Gallium-68 and to reduce the high elution volume of aGallium-68 activity could be desorbed from PS-HWith the here described concentration system and metal purification technique, a low activity containing
Autor:
Boxue, Liu, Erik, de Blois, Wouter A P, Breeman, Mark W, Konijnenberg, Hubert T, Wolterbeek, Peter, Bode
Publikováno v:
Current radiopharmaceuticals. 8(2)
The aim of this study was to assess the accuracy of the results of whole-body measurements by comparison with the urine collection method in the PRRT with (177)Lu and furthermore to develop a more accurate method of paired measurements. Excreted samp
Publikováno v:
Current radiopharmaceuticals. 8(2)
Peptide Receptor Radionuclide Therapy (PRRT) with (177)Lu-DOTA-peptides requires (177)Lu with high specific activity (SA) and values740 GBq (177)Lu per mg Lu to maximise the atom% of (177)Lu over total Lu. Vendors provide SA values which are based on
Publikováno v:
Current radiopharmaceuticals. 9(1)
Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin analogs has become an established procedure for the treatment of patients suffering from inoperable neuroendocrine cancers over-expressing somatostatin receptors. Success of
Publikováno v:
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine. 76
(68)Gallium-PET ((68)Ga-PET) agents have significant clinical promise. The radionuclide can be produced from a (68)Ge/(68)Ga generator on site and is a convenient alternative to cyclotron-based PET isotopes. The short half-life of (68)Ga permits imag
Autor:
Wouter A P, Breeman, Marion, de Jong, Jack L, Erion, Joseph E, Bugaj, Ananth, Srinivasan, Bert F, Bernard, Dik J, Kwekkeboom, Theo J, Visser, Eric P, Krenning
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 43(12)
The 14-amino-acid peptide bombesin (BN) has a high affinity for the gastrin-releasing peptide (GRP) receptor that is expressed by a variety of tumors. Recently, high densities of GRP receptors were identified by in vitro receptor autoradiography in h
Autor:
Gerrit D, Slooter, Arend G J, Aalbers, Wouter A P, Breeman, Coen A, Hiemstra, Richard L, Marquet, Eric P, Krenning, Casper H J, van Eijck
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 43(12)
The aim of this animal study was to evaluate whether peptide receptor radionuclide therapy with (111)In-diethylenetriaminepentaacetic acid (DTPA)(0)-octreotide was able to reduce tumor growth even under tumor growth-stimulating conditions induced by
Autor:
Dirk Mueller, Ingo Klette, Richard P. Baum, M. Gottschaldt, Michael K. Schultz, Wouter A. P. Breeman
Publikováno v:
Bioconjugate Chemistry. 24:1969-1969